bims-glumda Biomed News
on CGM data in management of diabetes
Issue of 2025–04–27
thirteen papers selected by
Mott Given



  1. J Diabetes Sci Technol. 2025 Apr 24. 19322968251335934
      
    Keywords:  adverse events; continuous glucose monitor; diabetes; glucose error grid; percent agreement
    DOI:  https://doi.org/10.1177/19322968251335934
  2. J Diabetes Sci Technol. 2025 Apr 23. 19322968251334633
       BACKGROUND: Diabetes care is a major challenge of patients treated in hospitals. A continuous glucose monitoring system (CGM) provides a more comprehensive assessment of glucose control than capillary blood glucose measurements. Especially in emergencies, data on CGM use in inpatients are limited. To evaluate real-world usability, accuracy of an intermittent scanning and a real-time CGM in patients admitted due to diabetes emergencies was assessed.
    METHODS: In 151 patients admitted due to diabetes emergencies, this single-center prospective study investigated the mean absolute relative difference (MARD) in broad glycemic ranges. The CGM accuracy was evaluated by applying a modified version of the Food and Drug Administration (FDA) criteria for CGM use, Clark Error Grid (CEG), and Bland Altman analysis (BAA).
    RESULTS: Analysis of 1,498 CGM-/POC-glucose (CGM-/POC-G) pairs revealed a MARD of 10.8% with stepwise improvement from the hypoglycemic to the hyperglycemic range. The CEG analysis showed that 99.1% of all glucose values fell within the optimal or acceptable zones. BAA indicated that 96.0% of CGM-G values fell within the limits of the POC-G values. Day-by-day analysis of overall MARD revealed the highest MARD on the first day of CGM use, followed by consistent and stable MARD levels from day 2 onward until the end of wear time. Applying a modified version of the %20/20 agreement rate of the FDA criteria, 90.7% of CGM-G laid within ±20 mg/dl/±20% agreement rule.
    CONCLUSION: This study indicates the usability of CGM for inpatient diabetes care by demonstrating a high accuracy and reliability of CGM measurement.
    Keywords:  accuracy; continuous glucose monitoring (CGM); hospital; hyperglycemia; hypoglycemia; inpatient
    DOI:  https://doi.org/10.1177/19322968251334633
  3. Health Sci Rep. 2025 Apr;8(4): e70747
       Introduction: Continuous glucose monitoring (CGM) has significantly advanced diabetes management, evolving from early glucose testing methods to modern, FDA-approved systems. Despite its benefits, challenges related to data security, affordability, and awareness of CGM devices remain.
    Aim: This article explores the historical development, current advancements, and ongoing challenges of CGM systems in diabetes management. It aims to provide insights into how these technologies have transformed patient care and highlight areas needing further improvement.
    Methods: A comprehensive literature review was conducted, focusing on advancements in CGM technology. Sources included PubMed, Google Scholar, and recent guidelines and reviews on CGM systems and their impact on diabetes management.
    Results: The evolution from the Dextrostix test strip to modern CGM systems, including over-the-counter devices, has enhanced glucose monitoring and patient outcomes. Recent innovations, such as machine learning models for predicting glucose fluctuations, promise to improve diabetes management. However, issues like data security and device accessibility persist.
    Conclusion: To maximize the benefits of CGM systems, addressing data security, improving affordability, and increasing awareness of CGM devices are crucial. Continued advancements in CGM technology and supportive policies are essential for enhancing diabetes care and patient outcomes globally.
    Keywords:  FDA approval; continuous glucose monitoring (CGM); diabetes mellitus; glucose monitoring devices; over‐the‐counter CGM
    DOI:  https://doi.org/10.1002/hsr2.70747
  4. Sci Rep. 2025 Apr 23. 15(1): 14200
      High-precision polarimetry is crucial for sensing and imaging applications, particularly for glucose monitoring within the physiological range of 50 to 400 mg/dl. Traditional approaches often rely on polarisation modulation using magneto-optic or liquid crystal modulators, which require high voltages or currents, limiting their practicality for wearable or implantable devices. In this work, we propose a polarisation-switching technique that alternates between two discrete polarisation states, offering a low-power alternative with miniaturisation potential. Using this method, we achieved a Mean Absolute Relative Difference of 7.7% and a Standard Error of Prediction of 9.6 mg/dl across the physiological glucose range, comparable to commercial continuous glucose monitors. Our approach demonstrates a limit of detection of approximately 40 mg/dl, with measurements performed in phosphate-buffered saline spiked with glucose. This work establishes polarisation switching as a viable alternative for glucose sensing, providing a foundation for future development of wearable and implantable glucose monitoring systems. By eliminating power-intensive components, our approach addresses key limitations of traditional polarimetric methods, paving the way for more accessible and energy-efficient diabetes management technologies.
    Keywords:  CGM; Glucose sensing; Optical biosensor; Polarimetry; Polarisation switching
    DOI:  https://doi.org/10.1038/s41598-025-99367-0
  5. Commun Med (Lond). 2025 Apr 22. 5(1): 103
       BACKGROUND: Efficiently assessing glucose handling capacity is a critical public health challenge. This study assessed the utility of relatively easy-to-measure continuous glucose monitoring (CGM)-derived indices in estimating glucose handling capacities calculated from resource-intensive clamp tests.
    METHODS: We conducted a prospective study of 64 individuals without prior diabetes diagnosis. The study performed CGM, oral glucose tolerance tests (OGTT), and hyperglycemic and hyperinsulinemic-euglycemic clamp tests. We validated CGM-derived indices characteristics using an independent dataset from another country and mathematical models with simulated data.
    RESULTS: A CGM-derived index reflecting the autocorrelation function of glucose levels (AC_Var) is significantly correlated with clamp-derived disposition index (DI), a well-established measure of glucose handling capacity and predictor of diabetes onset. Multivariate and machine learning models indicate AC_Var's contribution to predicting clamp-derived DI independent from other CGM-derived indices. The model using CGM-measured glucose standard deviation and AC_Var outperforms models using commonly used diabetes diagnostic indices, such as fasting blood glucose, HbA1c, and OGTT measures, in predicting clamp-derived DI. Mathematical simulations also demonstrate the association of AC_Var with DI.
    CONCLUSIONS: CGM-derived indices, including AC_Var, serve as valuable tools for predicting glucose handling capacities in populations without prior diabetes diagnosis. We develop a web application that calculates these CGM-derived indices ( https://cgm-ac-mean-std.streamlit.app/ ).
    DOI:  https://doi.org/10.1038/s43856-025-00819-5
  6. Diabetes Technol Ther. 2025 Apr 17.
      Background: The use of continuous glucose monitoring (CGM) devices in managing type 1 diabetes (T1D) has been associated with improved glycemic control in individuals with T1D. A key challenge for CGMs, however, is achieving accuracy, particularly under conditions where glucose levels may fluctuate rapidly, such as during exercise. Another factor contributing to blood glucose variability is the menstrual cycle, during which hormonal fluctuations affect insulin sensitivity, leading to variable glucose levels. This study aimed to assess the accuracy of FreeStyle Libre-3 (FSL3) during continuous moderate-intensity aerobic exercise (CONT) performed in the follicular and luteal phases of the menstrual cycle in females with T1D. Methods: Participants underwent CONT sessions on a cycle ergometer, one in the follicular phase and one in the luteal phase of the menstrual cycle, at the Research Laboratory of the Faculty of Physiotherapy. Glucose levels were measured every 10 min using FSL3 and the YSI 2500 as a gold standard. Measurements began 20 min before CONT and continued for 20 min after exercise. Results: A total of 26 females (mean age 32.2 ± 6.1 years and mean duration of diabetes 16.4 ± 8.4 years) participated in this study. FSL3 showed significant differences compared with YSI glucose data for both phases of the menstrual cycle (about 16 mg/dL higher in FSL3). There were no differences in mean absolute relative differences (MARDs) between the follicular (16.06%) and luteal (16.43) phases. Moreover, exercise did not affect MARDs, which were 14.21% pre-exercise and 17.63% postexercise for the follicular phase and 14.95% pre-exercise and 17.71% postexercise for the luteal phase. Conclusions: The findings suggest that the accuracy of FSL3 is not affected by CONT, showing good accuracy levels in both phases of the menstrual cycle. Thus, this study is the first to examine the influence of the menstrual cycle and exercise on the accuracy of a CGM device. The study was also prospectively registered at clinicaltrials.gov (NCT06086067).
    Keywords:  accuracy; continuous glucose monitoring; menstrual cycle; moderate-intensity continuous aerobic exercise; type 1 diabetes
    DOI:  https://doi.org/10.1089/dia.2024.0558
  7. J Prim Care Community Health. 2025 Jan-Dec;16:16 21501319251330091
       INTRODUCTION: Continuous Glucose Monitors (CGMs) offer critical insight into glucose trends, aiding significantly in overall type 2 diabetes (T2DM) management. Few studies have evaluated pharmacist involvement in CGM management.
    METHODS: This was a retrospective study, conducted at two primary care offices within a community health system. The aim of this study was to assess pharmacist impact on the deprescribing of high-risk medications in patients with T2DM utilizing CGM data. The primary outcome was the percentage of patients that experienced deprescribing of a high-risk medication (defined as reduction or discontinuation in total daily dosage of insulin, sulfonylureas, and thiazolidinediones). The secondary outcomes were rate of hospitalizations and changes in total daily insulin dose. Chi-square tests and t-tests were utilized to analyze primary and secondary outcomes.
    RESULTS: Among 317 participants, 58% of patients on CGMs had pharmacists involved in their care. Of patients in the pharmacist-led group, 11.4% experienced deprescribing of a high-risk medication compared to about 8.3% in the usual care group. Overall, hospitalizations were 3.2% lower in the pharmacist-led group compared to the usual care group during the study period. In addition, patients in the pharmacist-led group experienced a reduction in total daily insulin dose, while an increase in total daily insulin dosage for the usual care group was observed.
    CONCLUSION: While our study did not find a statistically significant difference in pharmacist-led deprescribing, there was a trend towards reduction in high-risk medication use. This suggests potential clinical significance, emphasizing the role of pharmacist involvement in prescribing practices of medications used to treat T2DM, including deprescribing high-risk medications and initiating non-high-risk medications with additional benefits. Further studies are needed to determine a difference in prescribing practice in pharmacist-led management of T2DM.
    Keywords:  community health; continuous glucose monitoring; diabetes mellitus; pharmacy; primary care
    DOI:  https://doi.org/10.1177/21501319251330091
  8. Diabetologia. 2025 Apr 24.
       AIMS/HYPOTHESIS: It has been proposed that severe hypoglycaemia events (SHE) may increase the risk of adverse CVD complications in adults with type 1 diabetes. The aim of this study was to evaluate the risk of CVD complications following SHE in a large cohort of adults with type 1 diabetes, and to compare the risk of post-SHE CVD complications for users of intermittently scanned continuous glucose monitoring (isCGM) vs users of blood glucose monitoring (BGM).
    METHODS: This comparative retrospective cohort study used data from the Swedish National Diabetes Register and the Swedish National Patient Register. We identified people with type 1 diabetes who had a hospitalisation for CVD complications. Rates of hospitalisation were compared between those with an index SHE and those without, and within isCGM or BGM subgroups. The study baseline was date of the first SHE prior to the isCGM index date.
    RESULTS: We identified 14,829 adults with type 1 diabetes with up to 2 years of follow-up, of which 1313 had an index SHE. In the full cohort, the relative rate of hospitalisations for CVD complications was 2.06-fold (95% CI 1.48, 2.85) in those with prior SHE. Of these 1313 participants with prior SHE, 970 were using isCGM and 343 were using BGM. Hospitalisations for post-SHE CVD complications were significantly lower for isCGM users (5.40 per 100 person-years of follow-up; 95% CI 4.59, 6.31) compared with BGM control participants (14.23 per 100 person-years of follow-up; 95% CI 11.95, 16.82), which represents a 78% relative reduction in rates of post-SHE CVD complications for isCGM users (relative rate 0.22; 95% CI 0.11, 0.43; p<0.001), after adjustment for confounders.
    CONCLUSIONS/INTERPRETATION: In adults with type 1 diabetes, SHE is associated with an increased risk of hospitalisation for adverse CVD complications. This risk is significantly reduced in isCGM users compared with BGM control participants.
    Keywords:  Cardiovascular; Hospitalisation; Intermittently scanned CGM; Major adverse cardiac events; Type 1 diabetes
    DOI:  https://doi.org/10.1007/s00125-025-06438-y
  9. Mater Today Bio. 2025 Jun;32 101746
      Biofouling is a significant concern in sensors and diagnostic applications as it results in reduced sensitivity, selectivity, and response time, false signals or noise, and ultimately causes a reduction in the sensor lifespan. This is particularly a concern while developing non-enzymatic glucose sensors (NEGS) that can be used to fabricate implantable sensors for continuous glucose monitoring. Thus, developing advanced materials solutions in the form of nanomaterials that display inherent antifouling activity is imperative. Due to their small nanosized dimensions and tunable microstructures, nanomaterials display unique physio-chemical properties that display antifouling efficiency and thus can be applied towards developing highly stable, sensitive, and selective NEGS. Through this review, we aim to explore the recent advances in the field of antifouling nanomaterials that offer promising potential to be applied towards developing NEGS. We discuss the details of various biofouling-resistant nanomaterials, including graphene and graphene oxide, carbon nanotubes, gold nanoparticles, silver nanoparticles, metal oxide nanoparticles, and polymeric nanocomposites. Further, we highlighted the possible mechanism of action involving nanomaterials in providing antifouling features in NEGS, followed by a brief discussion of the advantages and disadvantages of using nanomaterials for antifouling in developing NEGS. Finally, we concluded the article by proposing the future prospects of this promising technology.
    Keywords:  Antifouling; Biofouling; Glucose; NEGS; Nanomaterials; Sensors
    DOI:  https://doi.org/10.1016/j.mtbio.2025.101746
  10. Biosensors (Basel). 2025 Apr 16. pii: 255. [Epub ahead of print]15(4):
      Diabetes is a growing global health concern, affecting millions and leading to severe complications if not properly managed. The primary challenge in diabetes management is maintaining blood glucose levels (BGLs) within a safe range to prevent complications such as renal failure, cardiovascular disease, and neuropathy. Traditional methods, such as finger-prick testing, often result in low patient adherence due to discomfort, invasiveness, and inconvenience. Consequently, there is an increasing need for non-invasive techniques that provide accurate BGL measurements. Photoplethysmography (PPG), a photosensitive method that detects blood volume variations, has shown promise for non-invasive glucose monitoring. Deep neural networks (DNNs) applied to PPG signals can predict BGLs with high accuracy. However, training DNN models requires large and diverse datasets, which are typically distributed across multiple healthcare institutions. Privacy concerns and regulatory restrictions further limit data sharing, making conventional centralized machine learning (ML) approaches less effective. To address these challenges, this study proposes a federated learning (FL)-based solution that enables multiple healthcare organizations to collaboratively train a global model without sharing raw patient data, thereby enhancing model performance while ensuring data privacy and security. In the data preprocessing stage, continuous wavelet transform (CWT) is applied to smooth PPG signals and remove baseline drift. Adaptive cycle-based segmentation (ACBS) is then used for signal segmentation, followed by particle swarm optimization (PSO) for feature selection, optimizing classification accuracy. The proposed system was evaluated on diverse datasets, including VitalDB and MUST, under various conditions with data collected during surgery and anesthesia. The model achieved a root mean square error (RMSE) of 19.1 mg/dL, demonstrating superior predictive accuracy. Clarke error grid analysis (CEGA) confirmed the model's clinical reliability, with 99.31% of predictions falling within clinically acceptable limits. The FL-based approach outperformed conventional deep learning models, making it a promising method for non-invasive, privacy-preserving glucose monitoring.
    Keywords:  Clarke error grid analysis; deep neural networks (DNNs); diabetes management; federated learning (FL); healthcare; machine learning; non-invasive blood glucose monitoring; photoplethysmography (PPG)
    DOI:  https://doi.org/10.3390/bios15040255
  11. J Korean Med Sci. 2025 Apr 21. 40(15): e46
       BACKGROUND: To assess the quality of life (QoL) and treatment satisfaction with intermittently-scanned continuous glucose monitoring (isCGM) in women with gestational diabetes mellitus (GDM).
    METHODS: This prospective observational study included 189 women with GDM who completed the Korean version of the Audit of Diabetes-Dependent Quality of Life Questionnaire (K-ADDQoL). Among them, 25 women who utilized isCGM between gestational weeks 30 and 34 completed the Korean version of the Diabetes Treatment Satisfaction Questionnaire change version (K-DTSQc) to evaluate their satisfaction with isCGM during pregnancy.
    RESULTS: GDM had a negative impact on the perceived QoL in 89.4% of the women. All 19 domains of the K-ADDQoL were adversely influenced by GDM, with the most significant impact on the freedom to eat (weighted impact score, -6.98 ± 2.49, P < 0.001) and the least impact on the sex life (-0.25 ± 0.80, P = 0.008). Younger women and those treated with insulin perceived themselves as being more affected in their QoL due to GDM. Women perceived to have less effect on their QoL attributed to GDM exhibited higher ΔHbA1c one year after delivery (ΔHbA1c, 0.3 ± 0.4% vs. 0.0 ± 0.4% in less affected vs. more affected women). The utilization of isCGM improved treatment satisfaction (overall satisfaction score, 10.36 ± 9.21, P < 0.001), independent of glycemic control during pregnancy.
    CONCLUSION: Although GDM negatively affects the perceived QoL during pregnancy, attentiveness to GDM management may have a positive impact on long-term glycemic control. Moreover, employing isCGM can enhance treatment satisfaction in women with GDM.
    Keywords:  Continuous Glucose Monitoring; Diabetes, Gestational; Quality of life; Satisfaction
    DOI:  https://doi.org/10.3346/jkms.2025.40.e46
  12. Biosensors (Basel). 2025 Apr 15. pii: 250. [Epub ahead of print]15(4):
      This paper introduces a novel-shaped, compact, multiband monopole antenna sensor incorporating an irregular curved split-ring resonator (SRR) design for non-invasive, continuous monitoring of human blood glucose levels (BGL). The sensor operates at multiple resonance frequencies: 0.94, 1.5, 3, 4.6, and 6.3 GHz, achieving coefficient reflection impedance bandwidths ≤ -10 dB of 4%, 1%, 3.5%, 65%, and 50%, respectively. Additionally, novel shapes of two SRR metamaterial cells create notches at 1.7 GHz and 4.4 GHz. The antenna is fabricated on an economical FR4 substrate with compact dimensions of 35 × 50 × 1.6 mm3. The sensor's performance is evaluated using 3D electromagnetic software, incorporating a human finger phantom model and applying the Cole-Cole model to mimic the blood layer's sensitivity to blood glucose variations. The phantom model is positioned at different angles relative to the biosensor to detect frequency shifts corresponding to different glucose levels. Experimental validation involves placing a real human finger around the sensor to measure resonant frequency, magnitude, and phase changes. The fabricated sensor demonstrates a superior sensitivity of 24 MHz/mg/dL effectiveness compared to existing methods. This emphasizes its potential for practical, non-invasive glucose monitoring applications.
    Keywords:  continuous monitoring; glucose levels; monopole antenna; multiband and sensor; non-invasive; split-ring resonator (SRR)
    DOI:  https://doi.org/10.3390/bios15040250
  13. Biosensors (Basel). 2025 Apr 16. pii: 254. [Epub ahead of print]15(4):
      Noninvasive blood glucose monitoring is crucial for diabetes management, and photoacoustic spectroscopy (PAS) offers a promising solution by detecting glucose levels through human skin. However, weak acoustic signals in PAS systems require optimized resonator designs for enhanced detection sensitivity. Designing such resonators physically is complex, requiring the precise identification of critical parameters before practical implementation. This study focused on optimizing a T-shaped photoacoustic resonator using finite element modeling in a COMSOL Multiphysics environment. By systematically varying the geometric design parameters of the T-cell resonator, a maximum increase in the pressure amplitude of 12.76 times with a quality factor (Q-factor) of 47.5 was achieved compared to the previously designed reference acoustic resonator. This study took a significant step forward by identifying key geometric parameters that influence resonator performance, paving the way for more sensitive and reliable noninvasive glucose monitoring systems.
    Keywords:  Q-factor; T-cell; acoustic resonator; mid-infrared (MIR) spectroscopy; photoacoustic resonator (PAR); photoacoustic spectroscopy (PAS)
    DOI:  https://doi.org/10.3390/bios15040254